

Avecia Biologics customer achieves FDA approval to market a biologic to treat acute attacks of Hereditary Angioedema (HAE)

Billingham, UK, 2 December 2009 : Avecia Biologics has announced that Dyax Corp. (NASDAQ: DYAX), a customer for whom it has worked since 2000 on process development and GMP manufacturing, has received FDA approval of DX-88 in HAE. DX-88 is a recombinant, small protein manufactured in yeast (*P. pastoris*). The drug, which will be marketed as KALBITOR[®] (ecallantide), offers a new treatment option for treating acute attacks of HAE, a debilitating disease which causes severe, often painful swelling affecting the extremities (hands, feet, face, etc.), the gastrointestinal tract, the genitalia and, in potentially life-threatening cases, the larynx.

Avecia Biologics supported the clinical development programme of KALBITOR from Phase I supplies through scale-up, optimisation and process validation, and FDA pre-approval inspections for commercial manufacture.

Steve Bagshaw, President Avecia Biologics, said “We are delighted that Dyax has received FDA approval for KALBITOR. This is the culmination of a long and exciting period of collaboration and we now look forward to continuing to help Dyax bring relief to sufferers of this debilitating disease by ensuring safe, compliant and cost effective manufacturing.”

ENDS

About Avecia

Avecia is a privately owned biotechnology group of contract development and manufacturing companies with recognised leading positions in the process development and manufacture of microbial-derived biopharmaceuticals and oligonucleotide medicines. The group's Biologics Business, based at Billingham in the north east of the UK has been developing processes and making protein-based biologics to cGMP since 1998. Products currently being worked on include medicines targeted at forms of cancer, heart disease and stroke. In Milford, MA, the

group's OligoMedicines business carries out process development and manufacture of oligonucleotide therapeutics by sequential solid state synthesis to produce pharmaceuticals comprised of short strands of DNA or RNA. Customers range from some of the world's largest pharmaceutical companies to small innovative biotech start-up businesses.

For further information contact:

Bridget Hall

Communications Manager

Tel : +44 (0)1642 367320

Mobile : +44 (0)7796 938929

Fax : +44 (0)1642 364463

E-mail : bridget.hall@avecia.com